Global Expression Vectors Market Overview
Expression Vectors Market Size was valued at USD 0.3 Billion in 2023. The expression vectors market industry is projected to grow from USD 0.37 Billion in 2024 to USD 0.603 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.00% during the forecast period (2024 - 2032). The rise in infectious diseases and genetic abnormalities and the demand for biologics are the key market drivers driving the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Expression Vectors Market Trends
- Growing frequency of genetic abnormalities and chronic diseases is driving the market growth
Both generative expression vectors require and accept as a response to the accelerating frequency of genetic disorders as well as chronic diseases. Besides, the World Health Organization's (WHO's) 2021 report reveals that non-communicable diseases (NCDs) are the cause of 41 million deaths every year, which accounts for 71% of all the deaths that occur. Non-communicable disease is found to be the cause of the death of approximately 15 million people between the age group of 30 and 69. Moreover, respiratory illnesses (4. 1 million), diabetes (1. 5 million), malignancies (9. Non-infectious diseases ranked high on the list of death-causing factors, such as cancer (9. 6 million), followed by cardiovascular diseases (17. 9 million), took up the lion's share of non-communicated diseases each year. It is foreseen that the increasing number of non-communicable disease patients will create a demand for biologics; thus, biologics will be used for chronic illness treatment. In the course of treating numerous medical conditions, biologics vectors have proven to be quite important. These vectors provide viable ways to cure diseases at the genetic level by acting as carriers of therapeutic genes into target cells. Customizable expression vectors that may effectively transport therapeutic payloads to particular cell types while minimizing off-target effects are becoming more and more necessary as the emphasis on precision medicine and tailored therapeutics grows. The market CAGR is expanding as a result of the innovation in vector design and distribution systems that this need has sparked.
Besides, biopharmaceuticals are drugs believed to come from living things or their parts. Among them, vaccines, hormones, cytokines, monoclonal antibodies, and recombinant proteins are included. Different from traditional small molecule drugs, biopharmaceuticals are often made with expression systems that contribute to the genetic modification of host cells and result in the production of desired therapeutic proteins. Biopharmaceuticals, "monoclonal antibodies," are quite widely applied to treat various conditions, for example, infectious diseases, autoimmune diseases, or cancer. Mammalian cell expression systems of CHO cells are the most conventional media used in the formulation of monoclonal antibodies. These cells have to take up expression vectors and this process needs to be very efficient. Furthermore, as regards the rules concerning public funds, drug pricing, and intellectual property, the States stimulate biopharmaceutical innovation more than any other country. The Indian biotechnology sector is anticipated to have a valuation of over USD 92 billion by 2023, indicating a 15% rise from the previous year. The increase in biopharmaceutical production directly impacts the need for expression vectors. In a variety of host systems, expression vectors are essential for the production of monoclonal antibodies, recombinant proteins, and other biologics. The need for expression vectors will increase in tandem with the growth of the biopharmaceutical industry.
Moreover, biological systems or parts are designed and created by synthetic biology to fulfill particular functions or uses. As a means of delivering crafted genetic elements into host organisms for gene expression, expression vectors are vital to synthetic biology. Researchers can produce expression vectors from standardized genetic elements in a single step using synthetic biology platforms like Gibson Assembly and Golden Gate Assembly. Utilizing enzymes like Type IIS, these platforms are modular assembly systems that merge several DNA fragments into a single product. For high-throughput genetic engineering and functional genomics research, researchers can create custom expression vectors based on their experimental requirements. Likewise, novel expression systems with improved performance, selectivity, and regulatory control can be designed thanks to advances in synthetic biology technologies. By combining computational modeling, directed evolution techniques, and synthetic biology technology, researchers may produce expression vectors and host organisms with optimum gene expression features. In order to satisfy diverse scientific, medical, and industrial needs, businesses might utilize synthetic biology techniques to develop customized expression vector platforms, next-generation expression systems, and distinctive biotechnology solutions. The increasing progress in synthetic biology is expected to fuel market expansion and technological innovation by increasing the need for improved expression vector technologies. Thus, driving the expression vectors market revenue.
Expression Vectors Market Segment Insights
Expression Vectors Host Type Insights
The Expression Vectors Market segmentation, based on host type, includes Mammalian Expression Vectors, Insect Expression Vectors, Bacterial Expression Vectors, Yeast Expression Vectors, and Other Expression Vectors. In 2023, the bacterial expression vectors segment dominated the market. The disease occurrence and cancers contribute to this, as many companies have switched to bacterial and plasmid vectors. Bacteria, used as a carrier, leads to the delivery of recombinant proteins to target cells for the cure of diseases like infections and cancer. For instance, vectors of bacteria expression are frequently applied for their convenience, cheapness, and high level of expression. They are commonly applied in the business industry, protein synthesis, and molecular biological research.
Expression Vectors Application Insights
The Expression Vectors Market segmentation, based on application, includes Research Applications, Therapeutic Applications, and Industrial Applications. The research applications category generated the most income in 2023. The demand for research applications for expression vectors is growing steadily because of the expansion of research in various disciplines, such as synthetic biology, proteomics, drug discovery, and genomics. Also, project funding largely provided by both public and private agencies should bring to the fore the demand for expression vectors in the research application segment.
Figure 1: Expression Vectors Market, by Application, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Expression Vectors End User Insights
The Expression Vectors Market segmentation, based on end user, includes Pharmaceutical and Biotechnology Companies, Academic Research Institutes, and Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs). The pharmaceutical and biotechnology companies category generated the most income in 2023. Biotech and pharmacy companies are at the top in biotechnological industries as the biggest communicators of expression vectors. These companies employ expression vectors in the different stages of research, development, and medicine-making. Genetic engineering of biopharmaceuticals, including therapeutic proteins, vaccines, and mAbs, is only possible with genetic vectors that are used for that. Biotechnology and pharmaceutical sectors employ expression vector technologies for industrial-scale biologic manufacturing, high-throughput screening, and preclinical and clinical studies (GDPR 2021).
Expression Vectors Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American expression vectors market area will dominate this market. The region's growing scientific research and innovative technology development are the main elements contributing to its high share. Moreover, the market for expression vectors is growing as a result of rising investments made in biology research by both public and private American institutions.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: EXPRESSION VECTORS MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe expression vectors market accounts for the second-largest market share. The primary reasons that are expected to fuel this region's significant rise in the expression vectors market over the next seven years are improving healthcare infrastructure, growing biologics demand and awareness, and both. Further, the German expression vectors market held the largest market share, and the UK expression vectors market was the fastest growing market in the European region.
The Asia-Pacific Expression Vectors Market is expected to grow at the fastest CAGR from 2024 to 2032. The pharmaceutical and biotechnology industries' competitive growth, the expanding number of businesses engaging in biotechnology-related R&D, and the existence of significant market participants will all contribute to the region's success. Moreover, China’s expression vectors market held the largest market share, and the Indian expression vectors market was the fastest growing market in the Asia-Pacific region.
Expression Vectors Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the expression vectors market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, expression vectors industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global expression vectors industry to benefit clients and increase the market sector. In recent years, the expression vectors industry has offered some of the most significant advantages to medicine. Major players in the expression vectors market are attempting to increase market demand by investing in research and development operations, including GenScript USA, Promega Corporation, DNA2.0, Bio-Rad Laboratories, Merck Millipore, Sigma-Aldrich Corporation, New England Biolabs., Thermo Fisher Scientific, Agilent Technologies, and Clontech Laboratories, Inc.
The company Agilent Technologies Inc. (Agilent) supplies consumables, reagents, and analytical tools for use in laboratory operations. It also provides related services and software. Scientific research, patient diagnostics, and food, water, and pharmaceutical safety testing are the company's main areas of concentration. Among its product offerings include vacuum technologies, flow cytometry, microarray solutions, mass spectrometry, and others. Agilent serves a wide range of industries, including chemicals, applied materials, pharmaceuticals, diagnostics, contract research organizations (CROs), and contract manufacturing organizations (CMOs).
Biotechnology company Promega Corp (Promega) provides technological services and solutions to the government, industry, and academic life science sectors. Products for cell biology, molecular diagnostics, drug development, forensics and person identification, apparatus and labware, protein and RNA analysis, and DNA analysis are all available. Additionally, it offers services including target deconvolution, assay creation, cGMP production, bespoke manufacturing, customized product dispensing and formulation, and more.
Key companies in the expression vectors market include
- GenScript USA
- Promega Corporation
- Bio-Rad Laboratories
- Merck Millipore
- Sigma-Aldrich Corporation
- New England Biolabs.
- Thermo Fisher Scientific
- Agilent Technologies
- Clontech Laboratories, Inc.
Expression Vectors Industry Developments
February 2024: With the release of the NEBNext Enzymatic 5hmC-seq Kit, New England Biolabs made single-base precise enzyme-based 5hmC detection possible.
August 2022: Thermo Fisher Scientific expanded its capabilities in cell and gene therapy with the opening of a viral vector manufacturing plant in Plainville, Massachusetts.
February 2021: To expand worldwide pDNA development and production capabilities, Catalent bought Delphi Genetics and constructed a plasmid manufacturing plant in the United States.
Expression Vectors Market Segmentation
Expression Vectors Host Type Outlook
- Mammalian Expression Vectors
- Insect Expression Vectors
- Bacterial Expression Vectors
- Yeast Expression Vectors
- Other Expression Vectors
Expression Vectors Application Outlook
- Research Applications
- Therapeutic Applications
- Industrial Applications
Expression Vectors End User Outlook
- Pharmaceutical and Biotechnology Companies
- Academic Research Institutes
- Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs)
Expression Vectors Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
Report Attribute/Metric |
Details |
Market Size 2023 |
USD 0.3 Billion |
Market Size 2024 |
USD 0.37 Billion |
Market Size 2032 |
USD 0.603 Billion |
Compound Annual Growth Rate (CAGR) |
7.00% (2024-2032) |
Base Year |
2023 |
Market Forecast Period |
2024-2032 |
Historical Data |
2019-2022 |
Market Forecast Units |
Value (USD Billion) |
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
Segments Covered |
Host Type, Application, End User, and Region |
Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
Countries Covered |
The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
Key Companies Profiled |
GenScript USA, Promega Corporation, DNA2.0, Bio-Rad Laboratories, Merck Millipore, Sigma-Aldrich Corporation, New England Biolabs., Thermo Fisher Scientific, Agilent Technologies, and Clontech Laboratories, Inc. |
Key Market Opportunities |
·      Growth in the amount of money provided by the public and private sectors for specific research projects and the progress made in protein expression methods |
Key Market Dynamics |
·      Increasing rates of both acute and chronic illnesses, including diabetes, worldwide ·      Growing government spending on healthcare infrastructure |
Frequently Asked Questions (FAQ) :
The Expression Vectors Market size was valued at USD 0.3 Billion in 2023.
The global market is projected to grow at a CAGR of 7.00% during the forecast period, 2024-2032.
North America had the largest share in the global market
The key players in the market are GenScript USA, Promega Corporation, DNA2.0, Bio-Rad Laboratories, Merck Millipore, Sigma-Aldrich Corporation, New England Biolabs., Thermo Fisher Scientific, Agilent Technologies, and Clontech Laboratories, Inc.
The bacterial expression vectors category dominated the market in 2023.
The pharmaceutical and biotechnology companies category had the largest share in the global market.